EBI-005: Phase III started

Eleven began a double-blind, vehicle-controlled, U.S. Phase III trial to evaluate thrice-daily 5 mg/mL topical EBI-005 for up to 4 weeks in about 250 patients in an environmental setting. Eleven plans...